Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 263-271

  Kressel, Gaby ^a   Trunz, Birgit ^a   Bub, Achim ^b   Hülsmann, Olaf ^a   Wolters, Maike ^a   Lichtinghagen, Ralf ^c   Stichtenoth, Dirk O ^c   Hahn, Andreas ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adhesion molecules; C reactive protein; Insulin resistance; Metabolic syndrome; PAI 1

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; AGED; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 57649217610     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.04.012     Document Type: Article

References (61)

1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
2. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
3. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
4. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
5. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 38 (2006) 64-80
6. Muntner P., He J., Chen J., Fonseca V., and Whelton P.K. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 686-695
7. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-I10
8. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
9. Tracy R.P. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl (2003) 10-17
10. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
11. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
12. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
13. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97 (2006) 3A-11A
14. Stern S.E., Williams K., Ferrannini E., DeFronzo R.A., Bogardus C., and Stern M.P. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54 (2005) 333-339
15. Abbasi F., Brown Jr. B.W., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
16. Ridker P.M., Wilson P.W., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
17. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
18. de Ferranti S.D., and Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 16 (2007) 14-21
19. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
20. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17 (1997) 1121-1127
21. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
22. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
23. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102 (2000) 42-47
24. Guldiken S., Demir M., Arikan E., et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119 (2007) 79-84
25. Mavri A., Alessi M.C., and Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 255 (2004) 448-456
26. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16 (2000) 192-201
27. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
28. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 (1998) 1477-1482
29. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
30. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., and Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112 (2005) 3080-3087
31. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 (2005) 1215-1220
32. Montalescot G., Collet J.P., Choussat R., and Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 19 Suppl. H (1998) H11-H17
33. Juhan-Vage I. Haemostatic parameters and vascular risk. Atherosclerosis 124 Suppl. (1996) S49-S55
34. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
35. Ponthieux A., Herbeth B., Droesch S., Haddy N., Lambert D., and Visvikis S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 172 (2004) 299-308
36. Davies M.J., Gordon J.L., Gearing A.J., et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171 (1993) 223-229
37. van der Meer I., de Maat M.P., Bots M.L., et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam study. Arterioscler Thromb Vasc Biol 22 (2002) 838-842
38. Gearing A.J., and Newman W. Circulating adhesion molecules in disease. Immunol Today 14 (1993) 506-512
39. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252 (2002) 283-294
40. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96 (1997) 4219-4225
41. Pradhan A.D., Rifai N., and Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 106 (2002) 820-825
42. Blankenberg S., Rupprecht H.J., Bickel C., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104 (2001) 1336-1342
43. Schmitt B., Wolters M., Kressel G., et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis (2006)
44. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 54 (2005) 3252-3257
45. Gonzalez A.S., Guerrero D.B., Soto M.B., Diaz S.P., Martinez-Olmos M., and Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 60 (2006) 802-809
46. Wilson A.M., Ryan M.C., and Boyle A.J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106 (2006) 291-297
47. Feinbloom D., and Bauer K.A. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25 (2005) 2043-2053
48. Mavri A., Stegnar M., Krebs M., Sentocnik J.T., Geiger M., and Binder B.R. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 19 (1999) 1582-1587
49. Anand S.S., Yi Q., Gerstein H., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
50. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 28 (2004) 1357-1364
51. Aso Y., Wakabayashi S., Yamamoto R., Matsutomo R., Takebayashi K., and Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 28 (2005) 2211-2216
52. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., and Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152 (2000) 897-907
53. Juhan-Vague I., and Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 78 (1997) 656-660
54. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
55. Bahceci M., Tuzcu A., Ogun C., Canoruc N., Iltimur K., and Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in type 2 diabetic men with or without coronary heart disease?. J Endocrinol Invest 28 (2005) 145-150
56. Li J.J., and Fang C.H. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 62 (2004) 499-506
57. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
58. Peter K., Nawroth P., Conradt C., et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 17 (1997) 505-512
59. De Caterina, Basta G., Lazzerini G., et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 2646-2654
60. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-976
61. John S., Jacobi J., Delles C., Schlaich M.P., Alter O., and Schmieder R.E. Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. Clin Sci (Lond) 98 (2000) 521-529